Citius Pharmaceuticals, Inc. (CTXR) earnings
CTXR earnings moved a median of -6.09% by the close. Quarterly and annual CTXR reports and results, each read against the price at its own news timestamp. Back to the CTXR overview →
22 measured CTXR earnings events.
Where these CTXR earnings landedvs 22 measured CTXR earnings reactions
| Middle 50% of CTXR earnings reactions | -8.56% to +1.02% |
|---|---|
| Median reaction (to close) | -6.09% |
| Measured reactions | 22 |
Point-in-time · zero look-ahead
Half of the 22 CTXR earnings events with a measured close landed between -8.56% and +1.02%; 27% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update | Press release | -3.52% | -9.65% | |
| Form 10-Q Citius Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | -3.52% | -9.65% | |
| Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update | Press release | -10.95% | -7.54% | |
| Form 10-Q Citius Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | -10.95% | -7.54% | |
| Form 10-Q Citius Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-Q | +0.01% | -8.90% | |
| Form 10-K/A Citius Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-K | -3.55% | -3.75% | |
| Form 10-K Citius Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-K | -10.16% | -32.15% | |
| Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update | Press release | +2.34% | +2.40% | |
| Form 10-Q Citius Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | +2.34% | +2.40% | |
| Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update | Press release | -1.01% | -9.02% | |
| Form 10-Q Citius Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | -1.01% | -9.02% | |
| Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update | Press release | +0.39% | -3.14% | |
| Form 10-Q Citius Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-Q | +0.39% | -3.14% | |
| Form 10-K/A Citius Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-K | +0.99% | -3.64% | |
| Form 10-K Citius Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-K | -1.87% | +4.27% | |
| Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update | Press release | -5.55% | -6.09% | |
| Form 10-Q Citius Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | -5.55% | -6.09% | |
| Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update | Press release | +0.24% | -7.45% | |
| Form 10-Q Citius Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | +0.24% | -7.45% | |
| Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update | Press release | -0.86% | +8.18% | |
| Form 10-Q Citius Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-Q | -0.86% | +8.18% | |
| Form 10-K Citius Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-K | +2.57% | +6.41% |
Keep exploring
More CTXR: analyst actions → · SEC filings → · CTXR overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Xtant Medical Holdings, Inc. (XTNT) | 193 | 0.00% | 42% |
| Apollo Medical Holdings, Inc. (AMEH) | 192 | +0.16% | 55% |
| Kezar Life Sciences, Inc. (KZR) | 192 | +0.14% | 55% |
| TAKEDA PHARMA (TKPYY) | 192 | 0.00% | 47% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.